SlideShare una empresa de Scribd logo
1 de 1
Descargar para leer sin conexión
ATP III LDL cholesterol cutoffs for lifestyle interventions and drug therapy in different risk categories   Grundy SM et al.  Circulation ; available at http://circ.ahajournals.org Risk category LDL cholesterol goal Initiate therapeutic lifestyle changes Consider drug therapy High risk: CHD or CHD risk equivalents (10-year risk >20%) <100 mg/dL (with an optional goal of <70 mg/dL) > 100 mg/dL > 100 mg/dL (consider drug options if LDL-C <100 mg/dL) Moderately high risk: two or more risk factors (10-year risk 10%-20%) <130 mg/dL  (with an optional goal of <100 mg/dL)   > 130 mg/dL > 130 mg/dL (consider drug options if LDL-C 100-129 mg/dL) Moderate risk: two or more risk factors (10-year risk <10%) <130 mg/dL > 130 mg/dL >160 mg/dL Low risk:  < 1 risk factor <160 mg/dL > 160 mg/dL > 190 mg/dL (consider drug options if LDL-C 160-189 mg/dL)

Más contenido relacionado

La actualidad más candente

Dyslipidemia by dr. topu
Dyslipidemia by dr. topuDyslipidemia by dr. topu
Dyslipidemia by dr. topuNizam Uddin
 
Nafld management -_challenges_involved
Nafld management -_challenges_involvedNafld management -_challenges_involved
Nafld management -_challenges_involvedSantosh Narayankar
 
Basics of Systematic Review and Meta-analysis: Part 2
Basics of Systematic Review and Meta-analysis: Part 2Basics of Systematic Review and Meta-analysis: Part 2
Basics of Systematic Review and Meta-analysis: Part 2Rizwan S A
 
Evidence based management of Non Alcoholic fatty liver disease
Evidence based management of Non Alcoholic fatty liver diseaseEvidence based management of Non Alcoholic fatty liver disease
Evidence based management of Non Alcoholic fatty liver diseaseJayastu Senapati
 
Hypertension update 2018
Hypertension update 2018Hypertension update 2018
Hypertension update 2018Mahfuzul Islam
 
Randomised Controlled Trials
Randomised Controlled TrialsRandomised Controlled Trials
Randomised Controlled TrialsNinian Peckitt
 
Management of dyslipidemia 2019 update
Management of dyslipidemia  2019 update Management of dyslipidemia  2019 update
Management of dyslipidemia 2019 update Moustafa Mokarrab
 
Sample size for survival analysis - a guide to planning successful clinical t...
Sample size for survival analysis - a guide to planning successful clinical t...Sample size for survival analysis - a guide to planning successful clinical t...
Sample size for survival analysis - a guide to planning successful clinical t...nQuery
 
Randomization: Too Important to Gamble with.
Randomization: Too Important to Gamble with.Randomization: Too Important to Gamble with.
Randomization: Too Important to Gamble with.Dennis Sweitzer
 
F test and ANOVA
F test and ANOVAF test and ANOVA
F test and ANOVAParag Shah
 
Management of dyslipidemia
Management of dyslipidemiaManagement of dyslipidemia
Management of dyslipidemiaRajesh Rayidi
 
Systematic review and meta analaysis course - part 2
Systematic review and meta analaysis course - part 2Systematic review and meta analaysis course - part 2
Systematic review and meta analaysis course - part 2Ahmed Negida
 

La actualidad más candente (20)

Dyslipidemia by dr. topu
Dyslipidemia by dr. topuDyslipidemia by dr. topu
Dyslipidemia by dr. topu
 
Nafld management -_challenges_involved
Nafld management -_challenges_involvedNafld management -_challenges_involved
Nafld management -_challenges_involved
 
dyslipidemia6.ppt
dyslipidemia6.pptdyslipidemia6.ppt
dyslipidemia6.ppt
 
Basics of Systematic Review and Meta-analysis: Part 2
Basics of Systematic Review and Meta-analysis: Part 2Basics of Systematic Review and Meta-analysis: Part 2
Basics of Systematic Review and Meta-analysis: Part 2
 
Evidence based management of Non Alcoholic fatty liver disease
Evidence based management of Non Alcoholic fatty liver diseaseEvidence based management of Non Alcoholic fatty liver disease
Evidence based management of Non Alcoholic fatty liver disease
 
Recent advances in dyslipidemia
Recent advances in dyslipidemiaRecent advances in dyslipidemia
Recent advances in dyslipidemia
 
Hypertension update 2018
Hypertension update 2018Hypertension update 2018
Hypertension update 2018
 
Randomised Controlled Trials
Randomised Controlled TrialsRandomised Controlled Trials
Randomised Controlled Trials
 
Management of dyslipidemia 2019 update
Management of dyslipidemia  2019 update Management of dyslipidemia  2019 update
Management of dyslipidemia 2019 update
 
Meta analysis
Meta analysisMeta analysis
Meta analysis
 
Sample size for survival analysis - a guide to planning successful clinical t...
Sample size for survival analysis - a guide to planning successful clinical t...Sample size for survival analysis - a guide to planning successful clinical t...
Sample size for survival analysis - a guide to planning successful clinical t...
 
Dyslipidemia
DyslipidemiaDyslipidemia
Dyslipidemia
 
The ESC/EAS Guidelines
The ESC/EAS GuidelinesThe ESC/EAS Guidelines
The ESC/EAS Guidelines
 
Randomization: Too Important to Gamble with.
Randomization: Too Important to Gamble with.Randomization: Too Important to Gamble with.
Randomization: Too Important to Gamble with.
 
Introduction to meta analysis
Introduction to meta analysisIntroduction to meta analysis
Introduction to meta analysis
 
F test and ANOVA
F test and ANOVAF test and ANOVA
F test and ANOVA
 
Dyslipidemia lecture
Dyslipidemia lectureDyslipidemia lecture
Dyslipidemia lecture
 
Management of dyslipidemia
Management of dyslipidemiaManagement of dyslipidemia
Management of dyslipidemia
 
Systematic review and meta analaysis course - part 2
Systematic review and meta analaysis course - part 2Systematic review and meta analaysis course - part 2
Systematic review and meta analaysis course - part 2
 
Experimental Studies
Experimental StudiesExperimental Studies
Experimental Studies
 

Destacado

Evaluation of stroke
Evaluation of strokeEvaluation of stroke
Evaluation of strokeDJ CrissCross
 
Treatment of acute stroke with neuroprotective agents
Treatment of acute stroke with neuroprotective agentsTreatment of acute stroke with neuroprotective agents
Treatment of acute stroke with neuroprotective agentsDr. Samiran Adhikari
 
New developments in the treatment of intracerebral hemorrhage. 2013
New developments in the treatment of intracerebral hemorrhage. 2013New developments in the treatment of intracerebral hemorrhage. 2013
New developments in the treatment of intracerebral hemorrhage. 2013Javier Pacheco Paternina
 
Thrombolytic therqapy in stroke 14.2.01
Thrombolytic therqapy in stroke 14.2.01Thrombolytic therqapy in stroke 14.2.01
Thrombolytic therqapy in stroke 14.2.01PS Deb
 
Unanswered questions in thrombolytic therapy for acute ischemic stroke. 2013
Unanswered questions in thrombolytic therapy for acute ischemic stroke. 2013Unanswered questions in thrombolytic therapy for acute ischemic stroke. 2013
Unanswered questions in thrombolytic therapy for acute ischemic stroke. 2013Javier Pacheco Paternina
 
Health Policy - Use of IV tPA for Acute Ischemic Strokes
Health Policy - Use of IV tPA for Acute Ischemic StrokesHealth Policy - Use of IV tPA for Acute Ischemic Strokes
Health Policy - Use of IV tPA for Acute Ischemic StrokesZach Jarou
 
Medicinal Cannabis in the Treatment of Parkinson's
Medicinal Cannabis in the Treatment of Parkinson'sMedicinal Cannabis in the Treatment of Parkinson's
Medicinal Cannabis in the Treatment of Parkinson'sJames Van Geelen
 
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following SciNeuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following SciAnnabel De Coster
 
Relative Contraindications for Thrombolysis in Acute Ischemic Stroke
Relative Contraindications for Thrombolysis in Acute Ischemic StrokeRelative Contraindications for Thrombolysis in Acute Ischemic Stroke
Relative Contraindications for Thrombolysis in Acute Ischemic StrokeSudhir Kumar
 
Fenofibrate Dissolution Enhancement-AIChE\' 08
Fenofibrate Dissolution Enhancement-AIChE\' 08Fenofibrate Dissolution Enhancement-AIChE\' 08
Fenofibrate Dissolution Enhancement-AIChE\' 08sanganwar
 
CHA2DS2-VASc, Score CHADS2 score, and Hasbled score
CHA2DS2-VASc,  Score CHADS2 score, and Hasbled scoreCHA2DS2-VASc,  Score CHADS2 score, and Hasbled score
CHA2DS2-VASc, Score CHADS2 score, and Hasbled scoreDJ CrissCross
 
2013 ACC/AHA LIPID GUIDELINES
2013 ACC/AHA LIPID GUIDELINES2013 ACC/AHA LIPID GUIDELINES
2013 ACC/AHA LIPID GUIDELINESSubhasish Deb
 
Agents used in dyslipidemia: DGK
Agents used in dyslipidemia: DGKAgents used in dyslipidemia: DGK
Agents used in dyslipidemia: DGKDivya Krishnan
 
Stroke emergency treatment
Stroke emergency treatmentStroke emergency treatment
Stroke emergency treatmentPS Deb
 
New cholesterol treatment guidelines 2013
New cholesterol treatment guidelines 2013New cholesterol treatment guidelines 2013
New cholesterol treatment guidelines 2013Ramachandra Barik
 
Stroke and neuroprotection
Stroke and neuroprotectionStroke and neuroprotection
Stroke and neuroprotectionwebzforu
 

Destacado (20)

Evaluation of stroke
Evaluation of strokeEvaluation of stroke
Evaluation of stroke
 
Treatment of acute stroke with neuroprotective agents
Treatment of acute stroke with neuroprotective agentsTreatment of acute stroke with neuroprotective agents
Treatment of acute stroke with neuroprotective agents
 
New developments in the treatment of intracerebral hemorrhage. 2013
New developments in the treatment of intracerebral hemorrhage. 2013New developments in the treatment of intracerebral hemorrhage. 2013
New developments in the treatment of intracerebral hemorrhage. 2013
 
Thrombolytic therqapy in stroke 14.2.01
Thrombolytic therqapy in stroke 14.2.01Thrombolytic therqapy in stroke 14.2.01
Thrombolytic therqapy in stroke 14.2.01
 
Unanswered questions in thrombolytic therapy for acute ischemic stroke. 2013
Unanswered questions in thrombolytic therapy for acute ischemic stroke. 2013Unanswered questions in thrombolytic therapy for acute ischemic stroke. 2013
Unanswered questions in thrombolytic therapy for acute ischemic stroke. 2013
 
Statin combinations
Statin combinationsStatin combinations
Statin combinations
 
Health Policy - Use of IV tPA for Acute Ischemic Strokes
Health Policy - Use of IV tPA for Acute Ischemic StrokesHealth Policy - Use of IV tPA for Acute Ischemic Strokes
Health Policy - Use of IV tPA for Acute Ischemic Strokes
 
Medicinal Cannabis in the Treatment of Parkinson's
Medicinal Cannabis in the Treatment of Parkinson'sMedicinal Cannabis in the Treatment of Parkinson's
Medicinal Cannabis in the Treatment of Parkinson's
 
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following SciNeuroprotective Agents To Reduce Neuronal Loss Following Sci
Neuroprotective Agents To Reduce Neuronal Loss Following Sci
 
Relative Contraindications for Thrombolysis in Acute Ischemic Stroke
Relative Contraindications for Thrombolysis in Acute Ischemic StrokeRelative Contraindications for Thrombolysis in Acute Ischemic Stroke
Relative Contraindications for Thrombolysis in Acute Ischemic Stroke
 
Neuroprotection in stroke
Neuroprotection in strokeNeuroprotection in stroke
Neuroprotection in stroke
 
Fenofibrate Dissolution Enhancement-AIChE\' 08
Fenofibrate Dissolution Enhancement-AIChE\' 08Fenofibrate Dissolution Enhancement-AIChE\' 08
Fenofibrate Dissolution Enhancement-AIChE\' 08
 
CHA2DS2-VASc, Score CHADS2 score, and Hasbled score
CHA2DS2-VASc,  Score CHADS2 score, and Hasbled scoreCHA2DS2-VASc,  Score CHADS2 score, and Hasbled score
CHA2DS2-VASc, Score CHADS2 score, and Hasbled score
 
Stroke class
Stroke classStroke class
Stroke class
 
แผนFenofibrate pdf
แผนFenofibrate pdfแผนFenofibrate pdf
แผนFenofibrate pdf
 
2013 ACC/AHA LIPID GUIDELINES
2013 ACC/AHA LIPID GUIDELINES2013 ACC/AHA LIPID GUIDELINES
2013 ACC/AHA LIPID GUIDELINES
 
Agents used in dyslipidemia: DGK
Agents used in dyslipidemia: DGKAgents used in dyslipidemia: DGK
Agents used in dyslipidemia: DGK
 
Stroke emergency treatment
Stroke emergency treatmentStroke emergency treatment
Stroke emergency treatment
 
New cholesterol treatment guidelines 2013
New cholesterol treatment guidelines 2013New cholesterol treatment guidelines 2013
New cholesterol treatment guidelines 2013
 
Stroke and neuroprotection
Stroke and neuroprotectionStroke and neuroprotection
Stroke and neuroprotection
 

Similar a NCEP ATP III guidelines

Similar a NCEP ATP III guidelines (20)

Atglance
AtglanceAtglance
Atglance
 
Low Hdl Hyper Tg
Low Hdl Hyper TgLow Hdl Hyper Tg
Low Hdl Hyper Tg
 
Slides-Cholesterol.ppt
Slides-Cholesterol.pptSlides-Cholesterol.ppt
Slides-Cholesterol.ppt
 
Dyslipidemia 2016
Dyslipidemia 2016Dyslipidemia 2016
Dyslipidemia 2016
 
Dyslipidemia presentation.pptx
Dyslipidemia presentation.pptxDyslipidemia presentation.pptx
Dyslipidemia presentation.pptx
 
1GUIA TTO COLESTEROL
1GUIA TTO COLESTEROL1GUIA TTO COLESTEROL
1GUIA TTO COLESTEROL
 
DYSLIPIDEMIA AND RESIDUAL RISK
DYSLIPIDEMIA  AND  RESIDUAL RISKDYSLIPIDEMIA  AND  RESIDUAL RISK
DYSLIPIDEMIA AND RESIDUAL RISK
 
Dyslipidemia protocol
Dyslipidemia protocolDyslipidemia protocol
Dyslipidemia protocol
 
Dyslipidemia Guidlines
Dyslipidemia GuidlinesDyslipidemia Guidlines
Dyslipidemia Guidlines
 
Dyslipdemia Guidelines Head to Head
Dyslipdemia Guidelines Head to HeadDyslipdemia Guidelines Head to Head
Dyslipdemia Guidelines Head to Head
 
Primary prevention stroke
Primary prevention strokePrimary prevention stroke
Primary prevention stroke
 
Statin Wars
Statin WarsStatin Wars
Statin Wars
 
Lipid Guidelines - Dr. Ajay Kantharia
Lipid Guidelines - Dr. Ajay KanthariaLipid Guidelines - Dr. Ajay Kantharia
Lipid Guidelines - Dr. Ajay Kantharia
 
HYPERLIPIDEMIA.pptx
HYPERLIPIDEMIA.pptxHYPERLIPIDEMIA.pptx
HYPERLIPIDEMIA.pptx
 
Hypertensive Dyslipidaemics
Hypertensive DyslipidaemicsHypertensive Dyslipidaemics
Hypertensive Dyslipidaemics
 
Current lipid guidelines
Current lipid guidelinesCurrent lipid guidelines
Current lipid guidelines
 
Familial hypercholesterolemia
Familial hypercholesterolemiaFamilial hypercholesterolemia
Familial hypercholesterolemia
 
Statins
StatinsStatins
Statins
 
Dyslipidemia and Management of Dyslipidemia | Muhammad-Nizam-Uddin
Dyslipidemia and Management of Dyslipidemia | Muhammad-Nizam-UddinDyslipidemia and Management of Dyslipidemia | Muhammad-Nizam-Uddin
Dyslipidemia and Management of Dyslipidemia | Muhammad-Nizam-Uddin
 
L. berarducci new cholesterol management guidelines
L. berarducci new cholesterol management guidelinesL. berarducci new cholesterol management guidelines
L. berarducci new cholesterol management guidelines
 

Más de DJ CrissCross

2019 Novel Coronavirus
2019 Novel Coronavirus2019 Novel Coronavirus
2019 Novel CoronavirusDJ CrissCross
 
Aspirin for Primary Prevention of Cardiovascular Disease
Aspirin for Primary Prevention of Cardiovascular DiseaseAspirin for Primary Prevention of Cardiovascular Disease
Aspirin for Primary Prevention of Cardiovascular DiseaseDJ CrissCross
 
Acute Myocardial Infarction
Acute Myocardial InfarctionAcute Myocardial Infarction
Acute Myocardial InfarctionDJ CrissCross
 
Syndrome of inappropriate anti diuretic hormone secretion (siadh)
Syndrome of inappropriate anti diuretic hormone secretion (siadh)Syndrome of inappropriate anti diuretic hormone secretion (siadh)
Syndrome of inappropriate anti diuretic hormone secretion (siadh)DJ CrissCross
 
Vitamin B12 Deficiency
Vitamin B12 DeficiencyVitamin B12 Deficiency
Vitamin B12 DeficiencyDJ CrissCross
 
Clostridium difficile infection
Clostridium difficile infectionClostridium difficile infection
Clostridium difficile infectionDJ CrissCross
 
Hydrocarbon Toxicity
Hydrocarbon ToxicityHydrocarbon Toxicity
Hydrocarbon ToxicityDJ CrissCross
 
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis
Amyotrophic Lateral SclerosisDJ CrissCross
 
Emergencies In Oncology
Emergencies In OncologyEmergencies In Oncology
Emergencies In OncologyDJ CrissCross
 
Sjogren’s syndrome
Sjogren’s syndromeSjogren’s syndrome
Sjogren’s syndromeDJ CrissCross
 
Approach to a patient with JAUNDICE
Approach to a patient with JAUNDICEApproach to a patient with JAUNDICE
Approach to a patient with JAUNDICEDJ CrissCross
 
Paraneoplastic Endocrine Syndrome
Paraneoplastic Endocrine SyndromeParaneoplastic Endocrine Syndrome
Paraneoplastic Endocrine SyndromeDJ CrissCross
 
Physical Examination
Physical ExaminationPhysical Examination
Physical ExaminationDJ CrissCross
 
Diagnosis of Hyponatremia
Diagnosis of HyponatremiaDiagnosis of Hyponatremia
Diagnosis of HyponatremiaDJ CrissCross
 

Más de DJ CrissCross (20)

2019 Novel Coronavirus
2019 Novel Coronavirus2019 Novel Coronavirus
2019 Novel Coronavirus
 
Aspirin for Primary Prevention of Cardiovascular Disease
Aspirin for Primary Prevention of Cardiovascular DiseaseAspirin for Primary Prevention of Cardiovascular Disease
Aspirin for Primary Prevention of Cardiovascular Disease
 
CURB - 65
CURB - 65CURB - 65
CURB - 65
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
Acute Myocardial Infarction
Acute Myocardial InfarctionAcute Myocardial Infarction
Acute Myocardial Infarction
 
Syndrome of inappropriate anti diuretic hormone secretion (siadh)
Syndrome of inappropriate anti diuretic hormone secretion (siadh)Syndrome of inappropriate anti diuretic hormone secretion (siadh)
Syndrome of inappropriate anti diuretic hormone secretion (siadh)
 
Vitamin B12 Deficiency
Vitamin B12 DeficiencyVitamin B12 Deficiency
Vitamin B12 Deficiency
 
Stroke
StrokeStroke
Stroke
 
Clostridium difficile infection
Clostridium difficile infectionClostridium difficile infection
Clostridium difficile infection
 
Hydrocarbon Toxicity
Hydrocarbon ToxicityHydrocarbon Toxicity
Hydrocarbon Toxicity
 
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
 
Emergencies In Oncology
Emergencies In OncologyEmergencies In Oncology
Emergencies In Oncology
 
Esophageal Cancer
Esophageal CancerEsophageal Cancer
Esophageal Cancer
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Sjogren’s syndrome
Sjogren’s syndromeSjogren’s syndrome
Sjogren’s syndrome
 
Approach to a patient with JAUNDICE
Approach to a patient with JAUNDICEApproach to a patient with JAUNDICE
Approach to a patient with JAUNDICE
 
Paraneoplastic Endocrine Syndrome
Paraneoplastic Endocrine SyndromeParaneoplastic Endocrine Syndrome
Paraneoplastic Endocrine Syndrome
 
Emergencies in ENT
Emergencies in ENTEmergencies in ENT
Emergencies in ENT
 
Physical Examination
Physical ExaminationPhysical Examination
Physical Examination
 
Diagnosis of Hyponatremia
Diagnosis of HyponatremiaDiagnosis of Hyponatremia
Diagnosis of Hyponatremia
 

Último

ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 

Último (20)

ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 

NCEP ATP III guidelines

  • 1. ATP III LDL cholesterol cutoffs for lifestyle interventions and drug therapy in different risk categories Grundy SM et al. Circulation ; available at http://circ.ahajournals.org Risk category LDL cholesterol goal Initiate therapeutic lifestyle changes Consider drug therapy High risk: CHD or CHD risk equivalents (10-year risk >20%) <100 mg/dL (with an optional goal of <70 mg/dL) > 100 mg/dL > 100 mg/dL (consider drug options if LDL-C <100 mg/dL) Moderately high risk: two or more risk factors (10-year risk 10%-20%) <130 mg/dL (with an optional goal of <100 mg/dL) > 130 mg/dL > 130 mg/dL (consider drug options if LDL-C 100-129 mg/dL) Moderate risk: two or more risk factors (10-year risk <10%) <130 mg/dL > 130 mg/dL >160 mg/dL Low risk: < 1 risk factor <160 mg/dL > 160 mg/dL > 190 mg/dL (consider drug options if LDL-C 160-189 mg/dL)